Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital...
Congenital Adrenal HyperplasiaClassic Congenital Adrenal HyperplasiaThe purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of CRN04894 in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
Study of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Congenital Adrenal HyperplasiaThis study will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this study are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Congenital Adrenal HyperplasiaAn investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Autonomous Cortisol Secretion (ACS)ACTH-Independent Cushing Syndrome2 moreThis will be a study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment...
HypercortisolismDiabetes Mellitus1 moreThis is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to control T2D despite receiving standard of care therapies.
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children With CAH
Congenital Adrenal Hyperplasia21-OHDAn investigation of the safety and efficacy of tildacerfont in pediatric subjects with CAH.
A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
Congenital Adrenal HyperplasiaThis study is designed to evaluate the safety, tolerability, and efficacy of AAV5 based BBP-631 in adult participants diagnosed with classic congenital adrenal hyperplasia.
Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
HypercortisolismThis is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance and/or uncontrolled systolic hypertension.
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
Congenital Adrenal HyperplasiaThis is a controlled, open study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on clinical, anthropometric parameters, metabolic syndrome, hormonal profile, bone status, quality of life, reproductive, sexual and psychological functions and treatment compliance in patients affected by congenital adrenal hyperplasia due to 21 OH deficiency.
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
Cushing's Syndrome ICushing Disease Due to Increased ACTH Secretion4 moreThis is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor. Subjects will receive each of the following 2 treatments for 24 weeks: SPI-62 and matching placebo with the option of long-term extension.